Purpose
Guide health care providers in determining recommended vaccines for specific medical or other indications.
How to use the schedule
To make vaccination recommendations, healthcare providers should:
- Determine recommended vaccine by age (Table 1 - By Age)
- Assess need for additional recommended vaccinations by medical condition or other indication (Table 2 - By Medical Condition)
- Review vaccine types, dosing frequencies and intervals, and considerations for special situations (Notes)
- Review contraindications and precautions for vaccine types (Appendix)
Ages 19 Years or Older
Legend
| Recommended for all adults who lack documentation of vaccination, OR lack evidence of immunity | Not recommended for all adults, but recommended for some adults based on either age OR increased risk for or severe outcomes from disease | Recommended based on shared clinical decision-making | Recommended for all adults, and additional doses may be necessary based on medical condition or other indications. See Notes. | Precaution: Might be indicated if benefit of protection outweighs risk of adverse reaction | Contraindicated or not recommended *Vaccinate after pregnancy, if indicated | No Guidance/Not Applicable |
| Vaccine | Pregnancy | Immuno-compromised (excluding HIV infection) |
HIV infection CD4 percentage and count |
Men who have sex with men | Asplenia, complement deficiency | Heart or lung disease | Kidney failure, End-stage renal disease or on dialysis | Chronic liver disease; alcoholisma | Diabetes | Health care Personnelb | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| <15% or <200/mm3 | ≥15% and ≥200/mm3 | ||||||||||
COVID-19  |
See Notes | ||||||||||
| Influenza inactivated Influenza recombinant |
Solid organ transplant (See Notes) |
1 dose annually | |||||||||
| LAIV3 |
1 dose annually if age 19–49 years |
1 dose annually if age 19– | 49 years | ||||||||
| RSV |
Seasonal administration. (See Notes) | See Notes | See Notes |
Liver disease
(See Notes) |
See Notes
|
||||||
| Tdap or Td |
Tdap: 1 dose each pregnancy | 1 dose Tdap, then Td or Tdap booster every 10 yrs | |||||||||
| MMR |
* | ||||||||||
| VAR |
* | See Notes | |||||||||
| RZV |
See Notes | ||||||||||
| HPV |
* | 3-dose series if indicated | |||||||||
| Pneumococcal |
|||||||||||
| HepA |
|||||||||||
| HepB |
See Notes | ||||||||||
| Age ≥ 60 years |
|||||||||||
| MenACWY |
|||||||||||
| MenB |
|||||||||||
| Hib |
HSCT: 3 dosesc | Asplenia: 1 dose |
|||||||||
| Mpox |
See Notes | See Notes | See Notes | ||||||||
| IPV |
Complete 3-dose series if incompletely vaccinated. Self–report of previous doses acceptable (See Notes) | ||||||||||
- Precaution for LAIV4 does not apply to alcoholism.
- See notes for influenza; hepatitis B; measles, mumps, and rubella; and varicella vaccinations.
- Hematopoietic stem cell transplant.
- Determine recommended vaccine by age (Table 1 - By Age)
- Assess need for additional recommended vaccinations by medical condition or other indication (Table 2 - By Medical Condition)
- Review vaccine types, dosing frequencies and intervals, and considerations for special situations (Notes)
- Review contraindications and precautions for vaccine types (Appendix)
Additional Information
Report
- Suspected cases of reportable vaccine-preventable diseases or outbreaks to your state or local health department
- Clinically significant adverse events to the Vaccine Adverse Event Reporting System (VAERS) at www.vaers.hhs.gov or (800-822-7967)
Questions or comments
Contact www.cdc.gov/cdc-info or 800-CDC-INFO (800-232-4636), in English or Spanish, 8 a.m.–8 p.m. ET, Monday through Friday, excluding holidays.
Helpful information
- Complete Advisory Committee on Immunization Practices (ACIP) recommendations
- ACIP Shared Clinical Decision-Making Recommendations
- General Best Practice Guidelines for Immunization (including contraindications and precautions)
- Vaccine information statements
- Manual for the Surveillance of Vaccine-Preventable Diseases
(including case identification and outbreak response)
Content Source:
National Center for Immunization and Respiratory Diseases